Immunocore reports 70% two‑year survival in early‑stage uveal melanoma trial
Immunocore presented Phase 1/2 data showing an estimated 70% overall survival at two years among 17 first‑line patients treated with brenetafusp plus KIMMTRAK for metastatic uveal melanoma. The median follow‑up was 29 months and the overall response rate was 29%, with a disease‑control rate of 71%. The safety profile was manageable, with cytokine‑release syndrome in 77% of combination patients. Immunocore plans to launch a randomized Phase 2/3 trial (DUET‑UVEAL) to further evaluate the regimen.
Why it matters
The company cites the upcoming Phase 2/3 trial as the next catalyst for the business. Successful later‑stage results could drive future revenue and affect the stock’s valuation.
Key facts
- 1Two‑year overall survival was estimated at 70% among 17 first‑line patients. stocktitan.net
- 2Median follow‑up was 29 months. tradingview.com
- 3Overall response rate in first‑line patients was 29%. investing.com
- 4Disease‑control rate reached 71%. investing.com
- 5Cytokine‑release syndrome occurred in 77% of combination patients. investing.com
- 6Immunocore plans to start the DUET‑UVEAL randomized Phase 2/3 trial. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.